


PRODUCT INFORMATION



Thiothixene

Item No. 23649

CAS Registry No.: 5591-45-7
Formal Name: N,N-dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]-9H-thioxanthene-2-sulfonamide
Synonyms: CP 12,252-1, NSC 108165, P 4657B, *cis*-Thiothixene
MF: C₂₃H₂₉N₃O₂S₂
FW: 443.6
Purity: ≥98%
UV/Vis.: λ_{max}: 230, 307 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Thiothixene is supplied as a crystalline solid. A stock solution may be made by dissolving the thiothixene in the solvent of choice, which should be purged with an inert gas. Thiothixene is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of thiothixene in these solvents is approximately 0.2 and 0.5 mg/ml, respectively.

Description

Thiothixene is a typical antipsychotic.¹ It selectively binds to dopamine D₂ over D₁, D₃, and D₄ receptors (K_s = 0.417, 338, 186.2, and 363.1 nM, respectively). Thiothixene also binds to various serotonin (5-HT), histamine H₁, α₁- and α₂-adrenergic, muscarinic acetylcholine, and sigma receptors (K_s = 15-5,754 nM) as well as the dopamine, norepinephrine, and serotonin transporters (K_s = 3.16-30 μM). *In vivo*, thiothixene reduces spontaneous and amphetamine-induced locomotor activity in rats.² It enhances latent inhibition, as measured by a decreased lick latency in response to light and foot shock stimuli, which is a measure of selective attention in rats.³ Thiothixene also increases competitive behavior in submissive mice, indicating antidepressant-like behavior.⁴ Formulations containing thiothixene have been used in the treatment of schizophrenia and bipolar mania.

References

1. Silvestre, J.S. and Prous, J. Research on adverse drug events. I. Muscarinic M₃ receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. *Methods Find. Exp. Clin. Pharmacol.* **27(5)**, 289-304 (2005).
2. Schaefer, G.J. and Michael, R.P. Drug interactions on spontaneous locomotor activity in rats. Neuroleptics and amphetamine-induced hyperactivity. *Neuropharmacology* **23(8)**, 909-914 (1984).
3. Dunn, L.A., Atwater, G.E., and Kilts, C.D. Effects of antipsychotic drugs on latent inhibition: Sensitivity and specificity of an animal behavioral model of clinical drug action. *Psychopharmacology (Berl)*. **112(2-3)**, 315-323 (1993).
4. Malatynska, E., Rapp, R., Harrawood, D., *et al.* Submissive behavior in mice as a test for antidepressant drug activity. *Pharmacol. Biochem. Behav.* **82(2)**, 306-313 (2005).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/02/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM